Haycox A, Dubois D, Butterworth M
Department of Pharmacology and Therapeutics, University of Liverpool, England.
Pharmacoeconomics. 1998;14 Suppl 2:39-56. doi: 10.2165/00019053-199814002-00005.
The baseline economic model for upper gastrointestinal (UGI) disease was developed in the context of patterns of care and resource use within the UK. It provided the opportunity to evaluate the extent to which an economic model developed in one country could be applied to meet the pharmacoeconomic information needs of decision makers in another. The choice of countries for analysis was restricted to countries within the International Gastro Primary Care Group (IGPCG) who had previously agreed on the appropriateness of the basic clinical algorithm to their domestic healthcare environment. This provided a potential sample of 9 countries (Australia, Austria, Germany, Italy, The Netherlands, Sweden, Switzerland, the UK and the USA) of which the UK, Germany, Sweden and Switzerland were chosen as providing a broad spectrum of strategic and operating environments in which to test the international transferability of the economic model. The process and results obtained provide valuable evidence of the extent to which economic analyses can be transferred across national borders.
上消化道（UGI）疾病的基线经济模型是在英国的护理模式和资源使用背景下开发的。它提供了一个机会，来评估在一个国家开发的经济模型在多大程度上可以应用，以满足另一个国家决策者的药物经济学信息需求。分析所选择的国家仅限于国际胃肠初级保健集团（IGPCG）内的国家，这些国家之前已就基本临床算法对其国内医疗环境的适用性达成一致。这提供了一个潜在的9个国家的样本（澳大利亚、奥地利、德国、意大利、荷兰、瑞典、瑞士、英国和美国），其中英国、德国、瑞典和瑞士被选为提供广泛的战略和运营环境，以测试经济模型的国际可转移性。所获得的过程和结果为经济分析在多大程度上可以跨国转移提供了有价值的证据。
